| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
Medicine details |
|
| Medicine name | tralokinumab (Adtralza®) |
| Formulation | 150 mg solution for injection |
| Reference number | 3653 |
| Indication | Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy |
| Company | LEO Pharma |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/04/2021 |
| NICE guidance | TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |